Align Technology stock is supported by recent earnings metrics
Published on 07/21/2026 at 07:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Align Technology (US0162551016) can be framed today around its latest reported numbers: 2025 revenue reached $4.0 billion, diluted EPS was $6.43, and the company ended the year with $1.7 billion in cash and cash equivalents. The stock context can be built from those dated figures together with the latest market value available to the publisher.
Revenue and profit base
For 2025, Align Technology reported revenue of $4.0 billion, a figure that gives investors a clear reference point for the current operating base. Diluted EPS of $6.43 in 2025 and cash and cash equivalents of $1.7 billion show that the balance sheet remained substantial at year-end.
The comparison point matters as much as the absolute level. A $4.0 billion revenue base and $6.43 in diluted EPS provide the most concrete way to read the company’s current valuation backdrop, especially when the share price is being judged against a full-year operating result rather than a single trading session.
Cash and earnings mix
Align Technology also reported net income of $470.6 million for 2025, which helps anchor the earnings profile behind the stock. That figure sits alongside the $1.7 billion cash position and the $4.0 billion revenue line, giving the business a report-driven frame that is more useful than a simple brand description.
For a dental-device company with a large installed base, earnings quality often matters more than revenue alone. The 2025 net income figure of $470.6 million shows the level of profit the market can compare with prior periods when gauging whether the stock deserves a premium or discount.
Clearer focus on scale
The company’s 2025 results provide three hard metrics that investors can use immediately: $4.0 billion revenue, $470.6 million net income, and $6.43 diluted EPS. Together, they define the scale of the business better than any generic profile language could.
That mix is especially relevant because the stock is ultimately priced on earnings power, not just the brand behind Invisalign. The balance between sales scale, profit, and liquidity is what gives the name its market relevance.
Align Technology report metrics at a glance
The latest annual figures give a clean starting point for reading Align Technology stock through revenue, profit, and balance-sheet strength.
Invisalign remains the anchor
Invisalign remains the product most closely tied to Align Technology’s identity and revenue base. The product line matters because the 2025 results show how much earnings capacity the business can still generate from its core consumer and clinical demand.
For investors, the useful point is not product marketing but concentration: if a single platform remains the best-known commercial driver, then revenue durability and profit conversion remain central to any stock assessment.
Market view in one line
Align Technology stock should be read against the 2025 operating base rather than through a slogan or a brand story. Revenue of $4.0 billion, net income of $470.6 million, and diluted EPS of $6.43 are the numbers that define the setup.
Align Technology trades in US dollars on Nasdaq under the ticker ALGN.
Align Technology fact box
- Company: Align Technology, Inc.
- ISIN: US0162551016
- Ticker: NASDAQ: ALGN
- Trading venue: Nasdaq
- Sector / Industry: Health Care / Health Care Equipment
- Index membership: Nasdaq 100
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
